Georgia
NRx Pharmaceuticals begins Phase IIb Covid-19 vaccine trial in Georgia
The trial will evaluate BriLife’s potential to stimulate an immune response against the Delta variant of the SARS-CoV-2 virus.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox